MMTX.SW MINDMAZE THERAPEUTICS HOLDING SA
- Market cap
- CHF 27.5M
- P/E
- -
- P/B
- 0.74x
- ROE
- -25.8%
- Dividend yield
- -
- Fundamental score
- 0.7/5
Ratios use the latest price and the fiscal year ending Dec 2025.
Is MMTX.SW undervalued?
Graham numberThe Graham number of MINDMAZE THERAPEUTICS HOLDING SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MINDMAZE THERAPEUTICS HOLDING SA fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-27.6%), below 10%.
ROA 1/1
Return on assets (-22.5%) is above the industry median (-45.6%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Earnings growth cannot be compared with the industry.
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.7 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.7x) is below the industry median (3.1x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
MINDMAZE THERAPEUTICS HOLDING SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MINDMAZE THERAPEUTICS HOLDING SA
MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages pres…
Full company profileMINDMAZE THERAPEUTICS HOLDING SA financial statements
MINDMAZE THERAPEUTICS HOLDING SA annual financial statements (CHF; K = thousand, M = million, B = billion, T = trillion)
| Item | 2024 | 2025 |
|---|---|---|
| Income Statement | ||
| Revenue | 0.00 | 642K |
| Gross Profit | 0.00 | 591K |
| Operating Income | -2.00K | -10.5M |
| EBITDA | -1.00K | -8.00M |
| Net Income | -1.00K | -9.91M |
| EPS | - | -0.06 |
| Balance Sheet | ||
| Total Assets | 93.0K | 51.5M |
| Total Liabilities | 7.00K | 13.2M |
| Shareholders' Equity | 86.0K | 38.3M |
| Cash & Short-term Investments | 0.00 | 9.47M |
| Cash Flow | ||
| Operating Cash Flow | -3.00K | -7.21M |
| Capital Expenditure | 0.00 | 22.0K |
| Free Cash Flow | -3.00K | -7.23M |
| Ratios | ||
| ROE | -1.2% | -25.8% |
| ROA | -1.1% | -19.2% |
| Net Profit Margin | - | -1,543.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MINDMAZE THERAPEUTICS HOLDING SA dividends
MINDMAZE THERAPEUTICS HOLDING SA has not paid dividends in the last 2 fiscal years.
Who owns MINDMAZE THERAPEUTICS HOLDING SA
- Insiders 50.33%
- Institutions 18.73%
- Public & others 30.94%
- Shares outstanding 170M
- Free float 51.2M
MINDMAZE THERAPEUTICS HOLDING SA company profile
- Company name
- MINDMAZE THERAPEUTICS HOLDING SA
- Ticker
- MMTX.SW
- ISIN
- CH1251125998
- Exchange
- SIX Swiss Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Fiscal year end
- December
- Address
- Avenue de Sécheron 15, Geneva, Switzerland, 1202
- Phone
- 41 21 552 08 01
- Website
- mindmazetherapeutics.com
About MINDMAZE THERAPEUTICS HOLDING SA
MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages prescription, monitoring and documentation across MindMaze Therapeutics' neurotherapeutics ecosystem; and the patient app, a patient-facing mobile application, that supports clinic-to-home continuity by making prescribed therapy easy to follow outside the clinic. It also provides Izar hand therapy device which supports fine motor rehabilitation; Physilog sensor, a wearable inertial sensing device designed to quantify human movement; toaprun, a training for Parkinson's therapy-reimagined through play. The company was founded in 2012 and is headquartered in Geneva, Switzerland.
MINDMAZE THERAPEUTICS HOLDING SA management
4- Mr. Zachery W. HendersonCEO & Director · born 1973
- Mr. Jeremy Meinen CPAChief Financial Officer · born 1989
- Mr. Alexandre CapetChief Operating & Strategy Officer · born 1973
- Mr. Frédéric CondoloChief Technology Officer · born 1973